Quick & affordable screening diagnostic for biomarkers of neurodegenerative disease

Qualify patients & measure efficacy of treatment using visuospatial & cognitive deficits
Collaborate with us Today

Tracking disease progression is critical for creating effective interventions

Vision

We see a new standard of care where patients, clinicians, and researchers can quickly and easily identify neurodegenerative disease in-office, enabling opportunities to intervene to save individuals, families, and communities.

Mission

We increase patient access to care and clinical decision making ability with our screening diagnostic. Our AI tracks neurodegeneration by identifying visuospatial & cognitive deficits from EEG patterns that indicate specific levels of amyloid and tau protein accumulation as well as cognitive impairment.

Learn more about our progress

Vistim Labs’ high-resolution biomarkers correlate with traditional PET/CSF & cognitive endpoints

Would you like to publish together as research partners?

Collaborate with us Today

Relevant Press & Publications

VISTIM LABS WINS 1ST PLACE & $10K GRANT AT STARTUP SAN DIEGO COMPETITION

Read more

VISTIM LABS 1 OF 11 INVITED TO EXCLUSIVE ACCELERATOR, PHARMSTARS

Read more

CEO JAMES HAMET PUBLISHED FOR NOVEL EEG BIOMARKERS OF MENTAL FATIGUE

Read more